AlloVir Inc ALVR announced the presentation of long-term, follow-up data from the Phase 2 study of posoleucel to prevent infections from six viruses in allogeneic hematopoietic cell transplant (allo-HCT) recipients.
Posoleucel is the company's investigational, allogeneic, off-the-shelf, multi-virus specific T cell therapy, designed to target adenovirus, BK virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus-6 and JC virus.
These new findings demonstrate that high-risk allo-HCT patients who received posoleucel experienced continued low rates of clinically significant infections, end-organ disease, and 0% non-relapse mortality.
"The non-relapse mortality rate in patients receiving posoleucel was 0% through week 52, which compares favorably with published non-relapse mortality rates among allo-HCT patients ranging from 9% to over 15%," said Diana Brainard, CEO.
These new data demonstrate that, of the 26 patients dosed with posoleucel, the five deaths were all related to relapse/progression of underlying disease; none were due to infection or deemed treatment-related, resulting in 0% non-relapse mortality.
Global Phase 3 pivotal posoleucel trials continue with data readouts on track for 2024.
Price Action: ALVR shares are up 2.30% at $3.56 on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
